Navigation Links
$6.37 million from National Institutes of Health to find new ways to treat psoriasis
Date:11/6/2007

The National Institute of Arthritis and Musculoskeletal Skin Diseases (NIAMS), a research center at the National Institutes of Health (NIH), has awarded Case Western Reserve University School of Medicine and University Hospitals Case Medical Center a $6.37 million award to establish a Center of Research Translation (CORT) for the skin disease psoriasis.

This is one of the largest grants ever given to a medical institution in the United States for the study of psoriasis.

With a five-year grant from NIAMS, the Psoriasis CORT will bring a multidisciplinary team of translational physicians scientists, nurses, community clinicians, laity and basic scientists from different departments and disciplines together. This team will apply the intellectual and scientific resources of their institutions to new therapies to provide relief to patients with the skin disease that has long-term health and psychosocial consequences.

Our goal is to find ways to rebalance the human bodys immune system and skin cells to restrain the expression of this skin disease, said Kevin Cooper, M.D., department chair of dermatology at University Hospitals Case Medical Center (UHCMC) and professor of dermatology at the Case Western Reserve University School of Medicine. It is very important to obtain safe and durable remissions from disease because psoriasis has significant impact on patient health, spanning psychosocial effects, and risk for long-term cardiovascular complications and cancers.

The CORT grant complements a $5 million gift to University Hospitals Case Medical Center (UHCMC) from The Murdough Foundation that was received in December 2006 designed to advance the research and treatment of psoriasis. The gift remains the largest known in the United States for dermatology at an academic medical center. The Murdough Family Center for Psoriasis supports and stimulates clinical research and treatment for, and education about, psoriasis and creates a critical base for the CORT research projects and cores.

Together with the recently awarded $64 million NIH Clinical Translational Services Award to Case Western Reserve University and the NIH NIAMS Skin Diseases Research Center at Case Medical Center, the Psoriasis CORT concentrates a remarkable array of interactive research resources that we expect to change patient care with safer and better therapies, said Pamela Davis, dean of the Case Western Reserve University School of Medicine.

This CORT award reinforces University Hospitals Case Medical Centers dedication to, and progress with both the treatment and research of psoriasis, said Fred C. Rothstein, M.D., president and CEO of University Hospitals Case Medical Center. Our unique interdisciplinary approach to psoriasis therapy and study places us at the forefront of eventually curing this debilitating disease.

The NIAMS grant will allow research teams to focus on three projects that simultaneously utilize different strategies to study the disease.

  • PROJECT ONE: Researchers will test and explore the potential use in psoriasis of PC4, a novel photodynamic therapy (PDT), developed as a treatment for skin cancer at Case Western Reserve University by Malcolm Kenney, Ph.D., from the department of chemistry; Nancy Oleinick, Ph.D; and Drs. Cooper and Elma Baron at UHCMC.

    In a clinical trial, the non-invasive photosensitizer PC4 will be applied topically and exposed to red light to active the light-sensitive chemicals. After treatment, a real-time analysis of the psoriasis tissue will take place with the aid of a newly built device to conduct optical monitoring of tissue oxygen levels during treatments. The goal is to control inflammation that eventually brings on T-cell damage.

  • PROJECT TWO: Another focus of the Psoriasis CORT is to understand the role that S100A8/9, a pro-inflammatory protein, has in initiating the biochemical processes that result in the production of T-cells. Approximately 50 patients a year will participate in this area of the study.

    The research team hypothesizes that S100A8/9 is associated with a molecular pattern that recruits, activates and differentiates macrophage cells in the skin of patients with psoriasis and that blocking these processes will halt the progression of the disease.

  • PROJECT THREE: Through a study of genetically engineered mice with disease characteristics of psoriasis, the researchers hope to analyze the biochemical processes that create the signals leading to the disease and formulate strategies to block the signals. They also hope to study the cardiovascular risks associated with this disease in this mouse model.

Case Western Reserve and UHCMC are recognized as leaders in the study of psoriasis in multiple ways; the Skin Disease Research Center, which is one of only six NIH/NIAMS centers throughout the entire country; the Murdough Family Center for Psoriasis; NIH NIAMS research project funding; Veterans Administration translational clinical trial funding; and now the Psoriasis CORT.


'/>"/>

Contact: Susan Griffith
susan.griffith@case.edu
216-368-1004
Case Western Reserve University
Source:Eurekalert

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. AUDIO from Medialink and Pfizer: Number of Uninsured Americans Grows to 47 Million
3. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
4. 1.5 million children could be saved
5. The Philadelphia Walk Now for Autism Expected to Draw 10,000 Walkers and Raise $1 Million to Help Find Answers About the Nations Fastest-Growing Developmental Disorder
6. UVa researcher awarded $3.6 million grant to fight drug-resistant bacteria
7. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
8. R. P. Simmons Family Foundation Pledges $2 Million for New Childrens Hospital of Pittsburgh of UPMC Campus
9. £5 million investment in personalized medicines to cut patient deaths
10. Keane Wins $1 Million Electronic Medical Record (EMR) Implementation at New Jersey-Based Acute Care Facility
11. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... ... With over 60 percent of acute stroke survivors being left unable to ... in the rehabilitation process has steadily increased. Ekso Bionics had been working to help ... stroke. , Ekso Bionics has now received clearance from the U.S. Food and Drug ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed ... by inspiring human interest stories, courtesy of leaders in the nursing and health ... the industry, from leading advocates and associations—namely Jones & Bartlett Learning. , Jones ...
(Date:5/26/2016)... ... ... There are many ways to cook a hot dog, but new research commissioned ... dogs straight off the grill. Of the 90 percent of Americans who say they ... hot dog, far outpacing other cooking methods such as steaming (12 percent), microwaving (9 ...
(Date:5/26/2016)... ... ... Connor Sports, through its Connor Cares initiative, will continue to expand ... Tour that will commemorate the Indiana Fever legend’s hall-of-fame career and final WNBA ... levels of the game, Connor Sports has committed to a significantly increased focus on ...
(Date:5/26/2016)... ... ... MadgeTech will be showcasing its line of data logging products , ... MadgeTech headquarters. With products sold in more than 100 countries around the world, MadgeTech ... , In 2012, NASA strategically set up 17 RHTemp101A MadgeTech data loggers around ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... May 27, 2016 Amarantus BioScience Holdings, ... developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced ... presenting at two upcoming investor conferences: SeeThru Equity ... Avenue, New York City , NY ... Marcum MicroCap Conference   Where: Grand Hyatt Hotel, ...
(Date:5/26/2016)... , May 26, 2016 ... With Both Cost Savings and Overall Decreased ... (LSE: BTG), an international specialist healthcare company, has ... the 21st Annual Meeting of ISPOR (International Society ... of hepatocellular carcinoma (HCC) using yttrium-90 glass microspheres ...
(Date:5/25/2016)... -- According to a new market research ... by Therapeutic Area (Oncology, Cosmeceutical/Plastic Surgery), by Application (Drug ... Hospitals/ Clinics) - Forecast to 2021", published by MarketsandMarkets, ... the forecast period of 2016 to 2021. This market ... from USD 117.3 Million in 2016, at a CAGR ...
Breaking Medicine Technology: